Search research articles
Contact Us
Filters
Showing results (101-110 of 145) with videos related to
Page
of 15
Sort By:
The Lancet. Haematology
|
February 22, 2017
Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial
Andrés J M Ferreri, Marianna Sassone, Francesco Zaja, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 21, 2013
Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi
Umberto Vitolo, Marco Ladetto, Carola Boccomini, et al.
Leukemia & Lymphoma
|
November 25, 2016
Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I-II GIMEMA trial
Francesca R Mauro, Angelo M Carella, Stefano Molica, et al.
Rheumatology (Oxford, England)
|
September 5, 2022
Predicting lymphoma in Sjögren's syndrome and the pathogenetic role of parotid microenvironment through precise parotid swelling recording
Salvatore De Vita, Miriam Isola, Chiara Baldini, et al.
Haematologica
|
June 26, 2025
Use of second-line and beyond maintenance therapies in adult patients with primary immune thrombocytopenia in Europe: a parallel study of six prospective multicenter national registries
Guillaume Moulis, Frederick Chen, Giuseppe Carli, et al.
British Journal of Haematology
|
February 22, 2021
Eltrombopag second-line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off-treatment: results of a phase II, multicentre, prospective study
Elisa Lucchini, Francesca Palandri, Stefano Volpetti, et al.
Leukemia & Lymphoma
|
February 5, 2015
Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia
Alessandra Tedeschi, Paola Picardi, Simone Ferrero, et al.
American Journal of Hematology
|
October 7, 2017
Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers
Silvia Cantoni, Monica Carpenedo, Maria Gabriella Mazzucconi, et al.
Blood Advances
|
November 27, 2019
Updated international consensus report on the investigation and management of primary immune thrombocytopenia
Drew Provan, Donald M Arnold, James B Bussel, et al.
Blood
|
February 5, 2010
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia
Francesco Zaja, Michele Baccarani, Patrizio Mazza, et al.
Page
of 15
Search research articles
Search
Showing results (101-110 of 145) with videos related to
Sort By:
Page
of 15
The Lancet. Haematology
|
February 22, 2017
Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial
Andrés J M Ferreri, Marianna Sassone, Francesco Zaja, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 21, 2013
Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi
Umberto Vitolo, Marco Ladetto, Carola Boccomini, et al.
Leukemia & Lymphoma
|
November 25, 2016
Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I-II GIMEMA trial
Francesca R Mauro, Angelo M Carella, Stefano Molica, et al.
Rheumatology (Oxford, England)
|
September 5, 2022
Predicting lymphoma in Sjögren's syndrome and the pathogenetic role of parotid microenvironment through precise parotid swelling recording
Salvatore De Vita, Miriam Isola, Chiara Baldini, et al.
Haematologica
|
June 26, 2025
Use of second-line and beyond maintenance therapies in adult patients with primary immune thrombocytopenia in Europe: a parallel study of six prospective multicenter national registries
Guillaume Moulis, Frederick Chen, Giuseppe Carli, et al.
British Journal of Haematology
|
February 22, 2021
Eltrombopag second-line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off-treatment: results of a phase II, multicentre, prospective study
Elisa Lucchini, Francesca Palandri, Stefano Volpetti, et al.
Leukemia & Lymphoma
|
February 5, 2015
Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemia
Alessandra Tedeschi, Paola Picardi, Simone Ferrero, et al.
American Journal of Hematology
|
October 7, 2017
Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: A retrospective collaborative survey from Italian hematology centers
Silvia Cantoni, Monica Carpenedo, Maria Gabriella Mazzucconi, et al.
Blood Advances
|
November 27, 2019
Updated international consensus report on the investigation and management of primary immune thrombocytopenia
Drew Provan, Donald M Arnold, James B Bussel, et al.
Blood
|
February 5, 2010
Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia
Francesco Zaja, Michele Baccarani, Patrizio Mazza, et al.
Page
of 15